Diagnose Early Revenue and Competitors
Estimated Revenue & Valuation
- Diagnose Early's estimated annual revenue is currently $5.9M per year.
- Diagnose Early's estimated revenue per employee is $155,000
Employee Data
- Diagnose Early has 38 Employees.
- Diagnose Early grew their employee count by 36% last year.
Diagnose Early Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is Diagnose Early?
Founded by a Nobel Prize-winning team including Stanford M.D./Ph.D., Nobel Laureate, and a Harvard Business School/UW Madison Engineer. We are commercializing diagnostics for Cancer, Neurological, and Infectious Diseases, and are in clinical trials at Stanford University. The Diagnose Early team has patented a COVID-19 Acuity test titled D.E.C.A. that uses amino acid biomarkers found in breath to accurately and non-invasively predict the clinical course of each patient and therefore guide treatment.
keywords:N/A
N/A
Total Funding
38
Number of Employees
$5.9M
Revenue (est)
36%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Newark
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $8.2M | 38 | -5% | N/A |
#2 | $10M | 38 | 6% | N/A |
#3 | $6.9M | 38 | 65% | N/A |
#4 | $4.4M | 38 | 19% | N/A |
#5 | $9.9M | 38 | N/A | N/A |